Reneo Pharmaceuticals EBITDA vs. Cash And Equivalents

RPHMDelisted Stock  USD 18.20  1.40  8.33%   
Based on Reneo Pharmaceuticals' profitability indicators, Reneo Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Reneo Pharmaceuticals' ability to earn profits and add value for shareholders.
For Reneo Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Reneo Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Reneo Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Reneo Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Reneo Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reneo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Reneo Pharmaceuticals Cash And Equivalents vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Reneo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reneo Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Reneo Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in cash and equivalents category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Reneo Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Reneo Cash And Equivalents vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Reneo Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(82.23 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Reneo Pharmaceuticals

Cash

 = 

Bank Deposits

+

Liquidities

 = 
126.85 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Reneo Cash And Equivalents Comparison

Reneo Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Reneo Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Reneo Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Reneo Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Reneo Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Reneo Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.

Reneo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Reneo Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Reneo Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Reneo Pharmaceuticals' important profitability drivers and their relationship over time.

Use Reneo Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Reneo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reneo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Reneo Pharmaceuticals Pair Trading

Reneo Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Reneo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Reneo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Reneo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Reneo Pharmaceuticals to buy it.
The correlation of Reneo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Reneo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Reneo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Reneo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Reneo Pharmaceuticals position

In addition to having Reneo Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Index Thematic Idea Now

Macroaxis Index
Macroaxis Index Theme
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in Reneo Stock

If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stocks Directory
Find actively traded stocks across global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation